Measuring quality in arthritis care: The Arthritis Foundation's Quality Indicator Set for Rheumatoid Arthritis

Seminars in Arthritis and Rheumatism

Volumn 35, Issue 4, 2006, Pages 205-207

  Strand, Vibeke ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HUMAN; OSTEOARTHRITIS; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RESEARCH; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FOUNDATIONS; HUMANS; QUALITY INDICATORS, HEALTH CARE;

EID: 31844432572     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2005.09.006     Document Type: Editorial

References (24)

1. D. Khanna, E.L. Arnold, J.N. Pencharz Measuring process of arthritis care the Arthritis Foundation's quality set for rheumatoid arthritis Semin Arthritis Rheum 35 2005 211 237
2. C.H. Maclean, K.G. Saag, D.H. Solomon, S.C. Morton, S. Sampsel, J.H. Klippel Measuring quality in arthritis care methods for developing the Arthritis Foundation's quality indicator set Arthritis Rheum 51 2004 193 202
3. T.R. Mikuls, C.H. MacLean, J. Olivieri, F. Patino, J.J. Allison, J.T. Farrar Quality of care indicators for gout management Arthritis Rheum 50 2004 937 943
4. E.W. St Clair, D.M. van der Heidje, J.S. Smolen, R.N. Maini, J.M. Bathon, P. Emery Combination of infliximab and methotrexate therapy for early rheumatoid arthritis a randomized controlled trial Arthritis Rheum 50 2004 3432 3433
5. L. Klareskog, D. van der Heijde, J.P. de Jager, A. Gough, J. Kalden, M. Malaise Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis double-blind randomised controlled trial Lancet 363 2004 675 681
6. C.H. MacLean, S.C. Morton, K.J. Bulpitt, J.M. Grossman, M. Suareq-Almazor, S.B. Traina A systematic review of the effects of disease modifying antirheumatic drugs on radiographic progression in rheumatoid arthritis Arthritis Rheum 42 1999 S78
7. J.T. Sharp, V. Strand, H. Leung, F. Hurley Loew Friedrich, on behalf of the Leflunomide Rheumatoid Arthritis Investigators Group. Treatment with leflunomide slows radiographic progression of RA - results from 3 randomized controlled trials of leflunomide in patients with active rheumatoid arthritis Arthritis Rheum 43 2000 495 505
8. V. Strand, J. Sharp Radiographic data from recent randomized controlled trials in rheumatoid arthritis what have we learned? Arthritis Rheum 48 2003 21 34
9. P.A. Ory Interpreting radiographic data in rheumatoid arthritis Ann Rheum Dis 62 2003 597 604
10. G. Jones, H. Halbert, M. Crotty, E.M. Shanahan, M. Batterham, M. Ahern The effect of treatment on radiological progression in rheumatoid arthritis a systemic review of randomized placebo-controlled trials Rheumatology 42 2003 6 13
11. Y. Jiang, H.K. Genant, I. Watt, M. Cobby, B. Bresnihan, R. Aitchison A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis radiologic progression and correlation of Genant and Larsen scores Arthritis Rheum 43 2000 1001 1009
12. M.C. Genovese, J.M. Bathon, R.M. Martin, R.M. Fleischmann, J.R. Tesser, M.H. Schiff Etanercept versus methotrexate in patients with early rheumatoid arthritis Arthritis Rheum 46 2002 1443 1450
13. R.M. Fleischmann, J. Schechtman, R. Bennett, M.L. Handel, G.-R. Burmeister, J. Tesser Anakinra, a recombinant human interleukin-1 receptor antagonist, in patients with RA Arthritis Rheum 48 2003 927 934
14. E.C. Keystone, A.F. Kavanaugh, J.T. Sharp, H. Tannenbaum, Y. Hua, L.S. Teoh Radiographic, clinical and functional outcomes with adalimumab (a human anti-TNF monoclonal antibody) in the treatment of patients with active rheumatoid arthritis on concomitant methotrexate therapy a randomized, placebo-controlled, 52-week trial Arthritis Rheum 50 2004 1400 1411
15. D.M. van der Heijde, R.B. Landewe', P.E. Lipsky, R.N. Maini Radiological progression rate at baseline predicts treatment differences results from the ATTRACT trial [abstract] Arthritis Rheum 44 2001 S80
16. R.B. Landewe, D.M. van der Heijde, A. Verhoeven, A. Boonen, M. Boers, S. van der Linden Radiological progression rate at baseline predicts treatment differences results from the COBRA trial [abstract] Arthritis Rheum 44 2001 S371
17. V. Strand, R. Landewe, D. van der Heijde Using estimated yearly progression rates to compare radiographic data across recent randomized controlled trials in rheumatoid arthritis Ann Rheum Dis 61 2002 ii64 ii66
18. M. Boers COBRA Study Group Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial Arthritis Rheum 44 2001 2703 2704
19. E.T.H. Molenaar, A.E. Voskuyl, H.J. Dinant, P.D. Bezemer, M. Boers, A.C. Dijkmans Progression of radiographic damage in patients with rheumatoid arthritis in clinical remission Arthritis Rheum 50 2004 36 42
20. J.S. Smolen, C. Han, M. Bala, R.N. Maini, J.R. Kalden, D. van der Heijde Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study Arthritis Rheum 52 2005 1020 1030
21. F.C. Breedveld, M.H. Weisman, A.F. Kavanaugh, S.B. Cohen, K. Pavelka, R. Van Vollenhoven The efficacy and safety of adalimumab (humira®) plus methotrexate vs. adalimumab alone or methotrexate alone in the early treatment of rheumatoid arthritis (ra) 1- and 2-year results of the premier study Ann Rheum Dis 64 2005 SIII:60
22. FDA Arthritis Advisory Committee Meeting: 8/17/01: FDA briefing document: safety update on TNFα antagonists: infliximab and etanercept [online] available from http://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b2.htm [accessed 7/6/05].
23. FDA Arthritis Advisory Committee Meeting: 3/4/03: FDA briefing document: update on the TNFα blocking agents [online] available from http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930b1.htm [accessed 7/6/05].
24. D. Khanna, M. McMahon, D.E. Furst Safety of tumor necrosis factor α antagonists Drug Saf 27 2004 307 324